GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Piotroski F-Score

Bio-Techne (Bio-Techne) Piotroski F-Score : 6 (As of May. 11, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Bio-Techne Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bio-Techne has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Bio-Techne's Piotroski F-Score or its related term are showing as below:

TECH' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 9
Current: 6

During the past 13 years, the highest Piotroski F-Score of Bio-Techne was 9. The lowest was 3. And the median was 5.


Bio-Techne Piotroski F-Score Historical Data

The historical data trend for Bio-Techne's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Piotroski F-Score Chart

Bio-Techne Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 6.00 9.00 6.00

Bio-Techne Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 6.00 5.00 4.00 6.00

Competitive Comparison of Bio-Techne's Piotroski F-Score

For the Biotechnology subindustry, Bio-Techne's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 75.484 + 50.993 + 27.465 + 49.059 = $203 Mil.
Cash Flow from Operations was 83.393 + 59.383 + 83.116 + 80.986 = $307 Mil.
Revenue was 301.32 + 276.935 + 272.598 + 303.428 = $1,154 Mil.
Gross Profit was 204.698 + 185.191 + 176.587 + 204.599 = $771 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(2599.696 + 2638.692 + 2755.36 + 2730.753 + 2721.17) / 5 = $2689.1342 Mil.
Total Assets at the begining of this year (Mar23) was $2,600 Mil.
Long-Term Debt & Capital Lease Obligation was $482 Mil.
Total Current Assets was $611 Mil.
Total Current Liabilities was $150 Mil.
Net Income was 61.524 + 89.555 + 50.005 + 70.218 = $271 Mil.

Revenue was 288.228 + 269.655 + 271.581 + 294.146 = $1,124 Mil.
Gross Profit was 200.35 + 179.595 + 183.36 + 202.162 = $765 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(2299.892 + 2294.805 + 2350.721 + 2363.401 + 2599.696) / 5 = $2381.703 Mil.
Total Assets at the begining of last year (Mar22) was $2,300 Mil.
Long-Term Debt & Capital Lease Obligation was $463 Mil.
Total Current Assets was $571 Mil.
Total Current Liabilities was $141 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bio-Techne's current Net Income (TTM) was 203. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bio-Techne's current Cash Flow from Operations (TTM) was 307. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=203.001/2599.696
=0.07808644

ROA (Last Year)=Net Income/Total Assets (Mar22)
=271.302/2299.892
=0.11796293

Bio-Techne's return on assets of this year was 0.07808644. Bio-Techne's return on assets of last year was 0.11796293. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Bio-Techne's current Net Income (TTM) was 203. Bio-Techne's current Cash Flow from Operations (TTM) was 307. ==> 307 > 203 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=481.752/2689.1342
=0.17914762

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=463.267/2381.703
=0.19451082

Bio-Techne's gearing of this year was 0.17914762. Bio-Techne's gearing of last year was 0.19451082. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=610.65/149.82
=4.07589107

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=570.996/141.163
=4.04494095

Bio-Techne's current ratio of this year was 4.07589107. Bio-Techne's current ratio of last year was 4.04494095. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Bio-Techne's number of shares in issue this year was 160.496. Bio-Techne's number of shares in issue last year was 161.615. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=771.075/1154.281
=0.66801325

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=765.467/1123.61
=0.68125684

Bio-Techne's gross margin of this year was 0.66801325. Bio-Techne's gross margin of last year was 0.68125684. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=1154.281/2599.696
=0.44400615

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=1123.61/2299.892
=0.48854903

Bio-Techne's asset turnover of this year was 0.44400615. Bio-Techne's asset turnover of last year was 0.48854903. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bio-Techne has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Bio-Techne  (NAS:TECH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Bio-Techne Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne (Bio-Techne) Business Description

Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Executives
Roeland Nusse director 473 TENNESSEE, PALO ALTO CA 94306
William Geist officer: PRESIDENT, PROTEIN SCIENCES 900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth director, officer: Chief Executive Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Robert V Baumgartner director 5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
Kim Kelderman officer: Pres. Diagnostics & Genom 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor officer: SVP Biotech 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel officer: Chief Financial Officer 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan director C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Alpna Seth director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Julie L Bushman director 185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Randolph C Steer director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413

Bio-Techne (Bio-Techne) Headlines